- DehydraTECH™ is the company’s newly U.S.-patented disruptive drug delivery platform; LXRP CEO Chris Bunka says company is working on more applications for its technology in the treatment of Alzheimer’s disease, Parkinson’s disease, opioid addiction and more
- LXRP has a portfolio of patents issued in both the U.S. and Australia, plus 19 patent applications filed in the U.S. (and internationally using the Patent Cooperation Treaty), as well as national filings in 44 countries
- Company has diverse revenue streams, including out-licensing its technology to third parties with fees ranging from five to 10 percent of gross sales, as well as sales of its hemp oil cannabidiol (CBD) products, ranging from branded protein energy bars to premium teas
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka said in an audio interview with the Uptick Newswire Podcast (http://cnw.fm/FSyF0) that the company was not only surprised by how quickly it received its patent for DehydraTECH™; it was also surprised by the broadness of the patent awarded for its utilization in other sectors, which it had expected in 2018 and 2019. The company believes that the new patent has locked up the intellectual property (IP) for its next-generation drug delivery system.
“I probably think the company is more undervalued today than it was in the past,” Bunka stated in the interview. “It is potentially world-changing. The potential could deliver aspirin or Ibuprofen better than anyone else. That’s very profound.”
LXRP is a food bioscience company based in Kelowna, British Columbia, Canada, that is a technology disruptor for edible CBD. It markets a high absorption hemp oil formula, protein energy bars, exotic teas and high absorption hemp oil capsules to help the human body absorb CBD. Through potential partnerships, LXRP is now working on applying its technology to improving ingestion of several new products, such as beer, candies, cookies, capsules and pills. It owns international patent rights and has pending patents for its technology changing the way cannabinoids enter the body. Its technology provides increases in intestinal absorption rates, lower dosage size, more rapid delivery to the bloodstream and important taste-masking benefits.
Bunka also said the market does not completely understand the breadth and importance of the patent LXRP received, which also provided patent protection for potential treatment of Alzheimer’s disease, Parkinson’s disease, heart disease, opioid addition and more.
In summary, Bunka said, “The best is absolutely still to come in 2018, and I think it is going to make 2017 look boring in comparison.”
For more information, visit the company’s website at www.LexariaBioscience.com
More from CanadianCannabisWire
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CanadianCannabisWire.com